Archives
Crizotinib Hydrochloride in ALK Research
2026-08-19
Crizotinib hydrochloride is an ATP-competitive ALK kinase inhibitor that also targets c-Met and ROS1 for mechanism-driven cancer biology research. Its phosphorylation effects and solvent-specific handling data support controlled studies in cell systems and patient-derived models, but the product is not a clinical or diagnostic material.
SMAD3 Inhibition Lowers ADAMTS-5 in Early OA
2026-08-19
Xiang et al. identify a regulatory connection between SMAD3, miRNA-140, and ADAMTS-5 during early osteoarthritis. Their cell and rat experiments show that inhibiting SMAD3 increases miRNA-140 and reduces the cartilage-degrading enzyme ADAMTS-5, supporting a mechanistic framework for studying early extracellular-matrix loss.
Hydroxychloroquine Sulfate Workflow Guide
2026-08-18
Hydroxychloroquine Sulfate (SKU B4874) provides a water-compatible research reagent for examining autophagy pathway modulation and TLR7/9-dependent immune signaling in autoimmune disease research. It is suited to short-term aqueous workflows, but not to protocols requiring DMSO or ethanol solubility or long-term storage of prepared solutions.
EMD638683: A Mechanism-First SGK1 Inhibitor Guide
2026-08-18
EMD638683 is a selective SGK1 inhibitor for dissecting kinase-dependent sodium-channel signaling, endothelial stiffening, and tumor-cell stress. This guide focuses on causal assay design, target-engagement controls, and how to interpret vascular and oncology findings without overextending the evidence.
PD 173074 in LUAD Functional Assay Design
2026-08-17
PD 173074 can do more than inhibit FGFR1: it can help researchers functionally test drug-response patterns emerging from CENPO-centered lung adenocarcinoma studies. This article presents an assay strategy that connects FGFR signaling pathway inhibition with rigorous interpretation of genomic risk models.
GDC-0994: ERK1/2 Inhibition Beyond Oncology
2026-08-17
GDC-0994 offers a practical way to interrogate ERK1/2 as a convergent signaling node in both oncogenic tumors and estrogen-associated cholestatic injury. This translational perspective connects pathway biology, experimental design, target-engagement strategy, and the limitations that must be addressed before preclinical observations can inform therapeutic development.
Merbromin: Practical Fluorescence Assay Workflows
2026-08-16
Merbromin combines protein-binding fluorescence, enzyme inhibition, antimicrobial activity, and experimental tissue-marking utility in one research compound. This guide translates those properties into reproducible workflows, controls, troubleshooting steps, and evidence-aware application choices.
Catalpol, SDF-1α/CXCR4, and Ischemic Stroke
2026-08-15
This study identifies the SDF-1α/CXCR4 axis as a mechanistic link between Catalpol treatment, neural stem cell responses, and vascular remodeling after permanent cerebral ischemia. By combining a rat permanent middle cerebral artery occlusion model with oxygen–glucose deprivation assays, the authors provide preclinical evidence that Catalpol supports both neurogenesis and angiogenesis rather than targeting neuronal survival alone.
Halazone and Sodium Current Inactivation in Frog Nerves
2026-08-14
The reference study showed that Halazone and hypochlorous acid strongly disrupt sodium-current inactivation in voltage-clamped frog nerve fibers, while several other oxidants produce different effects. Its comparative reagent design argues against a uniquely essential methionine residue and instead supports membrane-lipid modification as a tentative explanation for altered channel kinetics.
Targeted SPP1 Inhibition Reprograms Tumor Myeloid Cells
2026-08-14
The reference study identifies a phenotypic small-molecule screening and nanomedicine strategy for reducing SPP1 expression in tumor-associated macrophages. Its lead modulator, CANDI460, lowered SPP1 in vitro and in vivo and reduced tumor burden across murine models, providing a complementary approach to broad macrophage depletion.
AAL-993: From Receptor Potency to Assay Design
2026-08-13
AAL-993 is a selective VEGF receptor inhibitor for dissecting angiogenic signaling, endothelial responses, and tumor–vascular interactions. This guide translates its kinase profile and the SFI glioma network-pharmacology study into practical assay and interpretation strategies.
Quizartinib (AC220): FLT3 Inhibition in AML
2026-08-13
Quizartinib, also known as AC220, is a selective FLT3 inhibitor for acute myeloid leukemia (AML) research. Its nanomolar biochemical potency, FLT3-pathway selectivity, cellular activity, and xenograft performance support mechanism-focused workflows, while resistance mutations and research-use limitations define important boundaries.
Cediranib (AZD2171): Designing Better Assays
2026-08-12
Cediranib (AZD2171) is a potent angiogenesis inhibitor whose pathway effects should not be confused with cell killing. This guide shows how to pair VEGFR signaling measurements with proliferation and death readouts for more interpretable cancer research.
Paclitaxel in Gastric Cancer Assembloid Screens
2026-08-12
Paclitaxel (Taxol) provides a mechanistically defined microtubule stress test for patient-derived gastric cancer assembloids. By comparing matched tumor organoids with stromal-containing models, researchers can distinguish direct tumor-cell sensitivity from microenvironment-mediated resistance.
Anlotinib hydrochloride: Angiogenesis Assay Workflows
2026-08-11
Anlotinib hydrochloride enables pathway-resolved studies of VEGFR2, PDGFRβ, and FGFR1 signaling across migration, tube formation, and ex vivo angiogenesis models. This workflow-focused guide shows how to distinguish genuine endothelial cell migration inhibition from nonspecific toxicity while extending the compound into comparative cancer research.
605 records 11/41 page Previous Next First page 上5页 1112131415 下5页 Last page